ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2004
Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Localizing motor entry points of adductor muscles of thigh for motor point procedures in the treatment of adductor spasticity.Anatomy & cell biology · 2024Article
- Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.The Cochrane database of systematic reviews · 2019Review
- Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.Journal of neurology · 2011Article
- Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2009Review
- Effect of botulinum toxin type-A in spasticity and functional outcome of upper limbs in cerebral palsy.Journal of clinical orthopaedics and traumaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was a retrospective survey of the management of a cohort of children with cerebral palsy at Seepark Hospital, Germany, who did (cases; n=107) and did not (controls; n=107) receive botulinum toxin injections. Data on healthcare resource use and clinical outcomes over 12 months were collected from the date cases received their first injection and from the date controls were first admitted into hospital. Botulinum toxin use led to an 85% reduction in the number of children requiring surgery. Additionally, controls used significantly more healthcare resources than cases, particularly hospital bed days (69.2+/-34.1 vs. 27.5+/-27.9 days; p <0.0001). The total cost of managing cases and controls was <euro>16,700 and <euro>33,800, respectively. In conclusion, use of botulinum toxin released resources for alternative use during the first year following treatment, without any loss of clinical improvement. However, it is unknown how botulinum toxin affected the need for surgery and associated outcomes in subsequent years.
Indexed as
Identifiers
15714343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.